Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03885011 · ClinicalTrials.gov registry record · Phase 2
A Multi-Center, Double-Masked Evaluation of the Efficacy and Safety of CSF-1 in the Treatment of Presbyopia
A Phase 2 study, sponsored by Orasis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 166
- Enrollment target
NCT03885011 is a Phase 2 study that has completed, run by Orasis Pharmaceuticals. The registered enrollment target is 166 participants.
The verdict
NCT03885011, a Phase 2 study, has completed, sponsored by Orasis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 166 participants
- Enrollment target
Study Summary
This is a 4-visit, multi-center, randomized, double-masked, parallel group study evaluating the safety and efficacy of CSF-1 in the treatment of presbyopia.
Interventions
- DRUG CSF-1
- DRUG CSF-1 Component #1
- DRUG CSF-1 Component #2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 166 participants |
| Start Date | 2019-02-26 |
| Est. Completion | 2019-07-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03885011
The ClinicalTrials.gov registry entry for NCT03885011 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 166 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Orasis Pharmaceuticals, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which CSF-1 is the first listed.
NCT03885011 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03885011 about?
NCT03885011 is a clinical study titled "A Multi-Center, Double-Masked Evaluation of the Efficacy and Safety of CSF-1 in the Treatment of Presbyopia". This is a 4-visit, multi-center, randomized, double-masked, parallel group study evaluating the safety and efficacy of CSF-1 in the treatment of presbyopia.
What is the current status of trial NCT03885011?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 166 participants. The study started on 2019-02-26. Estimated completion is 2019-07-26.
What interventions are being tested in trial NCT03885011?
The interventions under investigation include: CSF-1 (DRUG), CSF-1 Component #1 (DRUG), CSF-1 Component #2 (DRUG).
Who is sponsoring clinical trial NCT03885011?
This trial is sponsored by Orasis Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.